AR035612A1 - 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa - Google Patents
4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativaInfo
- Publication number
- AR035612A1 AR035612A1 ARP010105838A ARP010105838A AR035612A1 AR 035612 A1 AR035612 A1 AR 035612A1 AR P010105838 A ARP010105838 A AR P010105838A AR P010105838 A ARP010105838 A AR P010105838A AR 035612 A1 AR035612 A1 AR 035612A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- salts
- cognitive
- solvates
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000000474 nursing effect Effects 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 150000002148 esters Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 239000012453 solvate Substances 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000003937 drug carrier Substances 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- -1 -OH Chemical group 0.000 abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000004770 neurodegeneration Effects 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- OIYNIIJKRNGHJM-UHFFFAOYSA-N 4-(piperidin-4-ylmethyl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1CC1CCNCC1 OIYNIIJKRNGHJM-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 239000003149 muscarinic antagonist Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una 4-(piperidin-4-ilmetil)benzamida que tiene la fórmula estructural (1) o su sal, éster o solvato farmacéuticamente aceptable, donde en la fórmula estructural: R1 es R5-cicloalquilo C3-8, R5-cicloalquilo C3-8 alquilo C1-6, R5-arilo, R5-aril-alquilo C1-6 o R5-heteroarilo; R2 es H, alquilo C1-6, R6-cicloalquilo C3-8, R6-cicloalquil C3-8 alquilo C1-6, R6-heterocicloalquilo, R6-cicloalquilo C6-10 puenteado, o R6-heterocicloalquilo puenteado; R3 es alquilo C1-6 o -CH2OH; R4 es H o alquilo C1-6; R5 es 1-4 sustituyentes seleccionados independientemente entre el grupo que consiste en H, alquilo C1-6, halógeno, -OH, alcoxi C1-6, CF3, -CN, -CO2R4, -CONHR4, -SO2NHR4, -NHSO2R4 y -NHC(O)R4; y R6 es 1-4 sustituyentes seleccionados independientemente entre el grupo que consiste en H, alquilo C1-6, halógeno, -OH, alcoxi C1-6, CF3, -NH2, alquilamino C1-6, fenilo, alquilendioxi C1-2 y alcoxicarbonilo C1-6. Los compuestos, sales, ésteres, o solvatos farmacéuticamente aceptables, son antagonistas muscarínicos útiles para tratar trastornos cognitivos como ser la enfermedad de Alzheimer. Las composiciones farmacéuticas comprenden una cantidad terapéuticamente efectiva de los compuestos, sales, ésteres, o solvatos farmacéuticamente aceptables, en un portador farmacéuticamente aceptable. Los compuestos, sales, ésteres, o solvatos farmacéuticamente aceptables o de las composiciones, opcionalmente en combinación con un inhibidor de acetilcolinesterasa, se usan para preparar medicamentos para el tratamiento de enfermedades cognitivas o enfermedades neurodegenerativas. Los medicamentos se administran en una cantidad efectiva de los compuestos, sales, ésteres, o solvatos farmacéuticamente aceptables o de las composiciones a un mamífero que necesite de ese tipo de tratamiento. El kit para tratar una enfermedad cognitiva o enfermedad neurodegenerativa comprende en envases separados en un solo paquete, composiciones farmacéuticas para utilizar en combinación, en un envase un compuesto, sal, éster, o solvato farmacéuticamente aceptable, en un portador farmacéuticamente aceptable y en un segundo envase, un inhibidor de acetilcolinesterasa en un portador farmacéuticamente aceptable, siendo las cantidades combinadas en una cantidad efectiva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25785300P | 2000-12-22 | 2000-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035612A1 true AR035612A1 (es) | 2004-06-16 |
Family
ID=22978046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010105838A AR035612A1 (es) | 2000-12-22 | 2001-12-17 | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6458812B1 (es) |
| EP (1) | EP1343760B1 (es) |
| JP (2) | JP4012068B2 (es) |
| CN (1) | CN1481360A (es) |
| AR (1) | AR035612A1 (es) |
| AT (1) | ATE439344T1 (es) |
| AU (1) | AU2002235224A1 (es) |
| CA (1) | CA2431952C (es) |
| DE (1) | DE60139571D1 (es) |
| ES (1) | ES2329975T3 (es) |
| HK (1) | HK1054391A1 (es) |
| MX (1) | MXPA03005743A (es) |
| MY (1) | MY133992A (es) |
| PE (1) | PE20020657A1 (es) |
| WO (1) | WO2002051808A2 (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7700603B2 (en) * | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) * | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| EP1791904B1 (en) * | 2004-09-24 | 2014-08-27 | University of Maryland, Baltimore | Method of treating organophosphorous poisoning |
| US7678116B2 (en) | 2004-12-06 | 2010-03-16 | Dfine, Inc. | Bone treatment systems and methods |
| US7559932B2 (en) * | 2004-12-06 | 2009-07-14 | Dfine, Inc. | Bone treatment systems and methods |
| US7722620B2 (en) | 2004-12-06 | 2010-05-25 | Dfine, Inc. | Bone treatment systems and methods |
| EP1891021B1 (en) * | 2005-06-14 | 2019-01-23 | Merck Sharp & Dohme Corp. | Aspartyl protease inhibitors |
| US8110682B2 (en) | 2005-06-14 | 2012-02-07 | Schering Corporation | Preparation and use of compounds as aspartyl protease inhibitors |
| AU2006259572A1 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| US7812013B2 (en) * | 2005-06-14 | 2010-10-12 | Schering Corporation | Macrocyclic heterocyclic aspartyl protease inhibitors |
| US8722708B2 (en) | 2005-06-14 | 2014-05-13 | Merck Sharp & Dohme Inc. | Substituted isoindolines as aspartyl protease inhibitors |
| US20080027456A1 (en) * | 2006-07-19 | 2008-01-31 | Csaba Truckai | Bone treatment systems and methods |
| US8696679B2 (en) | 2006-12-08 | 2014-04-15 | Dfine, Inc. | Bone treatment systems and methods |
| EP2061771A1 (en) * | 2006-12-12 | 2009-05-27 | Schering Corporation | Aspartyl protease inhibitors containing a tricyclic ring system |
| CA2672293A1 (en) | 2006-12-12 | 2008-06-19 | Schering Corporation | Aspartyl protease inhibitors |
| WO2008137428A2 (en) | 2007-04-30 | 2008-11-13 | Dfine, Inc. | Bone treatment systems and methods |
| EP2200990A1 (en) | 2007-09-06 | 2010-06-30 | Schering Corporation | Gamma secretase modulators |
| CN101910178A (zh) | 2007-11-05 | 2010-12-08 | 先灵公司 | γ分泌酶调节剂 |
| JP2011506461A (ja) * | 2007-12-11 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼモジュレーター |
| RU2011123862A (ru) | 2008-11-13 | 2012-12-20 | Шеринг Корпорейшн | Модуляторы гамма-секретазы |
| EP2379563B1 (en) | 2008-12-22 | 2014-07-16 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| AR074702A1 (es) | 2008-12-22 | 2011-02-02 | Schering Corp | Moduladores de gamma secretasa y composiciones farmaceuticas que los contienen |
| CN102365269A (zh) * | 2009-03-26 | 2012-02-29 | 大日本住友制药株式会社 | 用于治疗认知缺损的新药物 |
| EP2443119A1 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
| EP2443121A2 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
| US20120232108A1 (en) | 2009-06-16 | 2012-09-13 | Xianhai Huang | Gamma secretase modulators |
| US20110281853A1 (en) | 2010-05-12 | 2011-11-17 | Rishi Arora | Compositions and methods for treating or preventing atrial fibrillation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04312572A (ja) * | 1991-04-12 | 1992-11-04 | Takeda Chem Ind Ltd | 環状アミン化合物 |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| TW542822B (en) * | 1997-01-17 | 2003-07-21 | Ajinomoto Kk | Benzamidine derivatives |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
-
2001
- 2001-12-17 CA CA002431952A patent/CA2431952C/en not_active Expired - Fee Related
- 2001-12-17 AU AU2002235224A patent/AU2002235224A1/en not_active Abandoned
- 2001-12-17 CN CNA018209718A patent/CN1481360A/zh active Pending
- 2001-12-17 MX MXPA03005743A patent/MXPA03005743A/es active IP Right Grant
- 2001-12-17 US US10/023,277 patent/US6458812B1/en not_active Expired - Fee Related
- 2001-12-17 AT AT01985584T patent/ATE439344T1/de not_active IP Right Cessation
- 2001-12-17 EP EP01985584A patent/EP1343760B1/en not_active Expired - Lifetime
- 2001-12-17 AR ARP010105838A patent/AR035612A1/es unknown
- 2001-12-17 HK HK03106691.6A patent/HK1054391A1/zh unknown
- 2001-12-17 ES ES01985584T patent/ES2329975T3/es not_active Expired - Lifetime
- 2001-12-17 WO PCT/US2001/049063 patent/WO2002051808A2/en not_active Ceased
- 2001-12-17 DE DE60139571T patent/DE60139571D1/de not_active Expired - Lifetime
- 2001-12-17 JP JP2002552905A patent/JP4012068B2/ja not_active Expired - Fee Related
- 2001-12-18 PE PE2001001266A patent/PE20020657A1/es not_active Application Discontinuation
- 2001-12-19 MY MYPI20015743A patent/MY133992A/en unknown
-
2007
- 2007-08-03 JP JP2007203608A patent/JP2007297410A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MY133992A (en) | 2007-11-30 |
| CA2431952C (en) | 2010-03-09 |
| MXPA03005743A (es) | 2003-09-05 |
| JP2007297410A (ja) | 2007-11-15 |
| JP2004516313A (ja) | 2004-06-03 |
| US6458812B1 (en) | 2002-10-01 |
| EP1343760A2 (en) | 2003-09-17 |
| WO2002051808A3 (en) | 2003-01-23 |
| JP4012068B2 (ja) | 2007-11-21 |
| AU2002235224A1 (en) | 2002-07-08 |
| HK1054391A1 (zh) | 2003-11-28 |
| CN1481360A (zh) | 2004-03-10 |
| CA2431952A1 (en) | 2002-07-04 |
| DE60139571D1 (de) | 2009-09-24 |
| ATE439344T1 (de) | 2009-08-15 |
| EP1343760B1 (en) | 2009-08-12 |
| WO2002051808A2 (en) | 2002-07-04 |
| PE20020657A1 (es) | 2002-07-23 |
| ES2329975T3 (es) | 2009-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035612A1 (es) | 4-(piperidin-4-ilmetil)benzamidas, o sus sales, esteres o solvatos, composiciones farmaceuticas que los comprenden, usos de los mismos para preparar medicamentos, y un kit para utilizar en el tratamiento de una enfermedad cognitiva o neurodegenerativa | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| JP7523450B2 (ja) | アミノ酸化合物およびその使用方法 | |
| ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
| AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| AR049956A1 (es) | DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS. | |
| AR017182A1 (es) | Compuestos de aminotiazol, inhibidores de las kinasas dependientes de ciclinas y las composiciones farmaceuticas que los contienen. | |
| ES2179353T3 (es) | Antagonistas muscarinicos. | |
| MX9606541A (es) | Aminoeteres aromaticos como agentes para aliviar el dolor. | |
| MX9706381A (es) | Antagonista muscararinicos. | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
| AR029634A1 (es) | Compuestos derivados heterociclicos utiles como agentes anticancerosos, composicion farmaceutica y procedimiento de tratamiento | |
| PE20020721A1 (es) | Derivados de quinuclidina como agentes antimuscarinicos m3 | |
| AR034390A1 (es) | Derivados de 1-sulfonil-tetrahidro quinolinas sustituidas, composiciones farmaceuticas y el uso de las mismas para la elaboracion de medicamentos como inhibidores de la gama secretasa | |
| AR077267A1 (es) | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| DOP2005000046A (es) | Compuestos de acido alfa arilo o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
| ES2714100T3 (es) | Compuestos de quinolina fusionados como inhibidores de mTor, pi3k | |
| AR016422A1 (es) | Compuestos de esteres ciclicos de piperidinilaminometil trifluorometilo como antagonista de la sustancia p; composiciones farmaceuticas y procedimientos detratamiento. | |
| JP2003508524A5 (es) | ||
| AR057835A1 (es) | Derivados de 9- azabiciclo (3.3.1)nonano y composicion farmaceutica | |
| AR041883A1 (es) | Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20240812A1 (es) | Arilsulfonil(hidroxi)piperidinas como inhibidores de ccr6 | |
| PE20251600A1 (es) | Compuestos que contienen heteroatomos y usos de estos | |
| AR055554A1 (es) | Compuestos piridinicos, composicion farmaceutica y uso de los compuestos para preparar medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |